Published: 22 February 2020
Author(s): Heloni M. Dave, Alok A. Khorana
Section: Editorial

The association of cancer with a clinical hypercoagulable state has been known for over 140 years but continues to be an important clinical problem. Despite rapid changes in cancer treatments, venous thromboembolism (VTE) remains associated with novel anti-cancer regimens. These include lenalidomide in multiple myeloma, immunotherapy agents in various solid tumors, cyclin dependent kinase inhibitors in breast cancer and anti-epidermal growth factor receptor antibodies in colorectal cancers [1–4].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.